1. Introduction {#sec1}
===============

Drug resistance has emerged as one of the greatest challenges facing malaria control. Due to widespread resistance in malaria parasites to multiple antimalarial drugs, WHO recommended artemisinin (ART)-based combination therapies (ACT) to be the frontline treatment of falciparum malaria since 2005. To our dismay, reports of resistance to ART and its partner drugs started emerging in 2006--2007 in the Greater Mekong Subregion (GMS) of Southeast Asia. First reports of reduced *in vivo* susceptibility to ART, characterized by delayed clearance of parasites, came from northwestern Cambodia after artesunate (AS) monotherapy or ACT ([@bib13]; [@bib33]) followed by numerous reports from other parts of GMS including Cambodia, Thailand, Vietnam, Myanmar, and the China-Myanmar border areas, due to spread, independent emergence, or both ([@bib5]; [@bib8]; [@bib9]; [@bib18]; [@bib22]; [@bib39]; [@bib43]). Spread of ART resistance from GMS to Africa would be catastrophic and an enormous threat to global malaria control programs. Such resistance creates an urgent need to identify molecular markers for the surveillance of ART-resistant parasites in order to contain the spread of resistance.

The two important phenotypes associated with ART resistance are delayed parasite clearance half-life (\>5 h) *in vivo* ([@bib4]; [@bib5]) and increased ring-stage survival rates *in vitro* after a brief ART exposure ([@bib54]). The ART-resistant mechanism was first identified in parasites cultured under ART drug pressure *in vitro* for over a period of five years, which involved a mutation (M476I) in the *Kelch 13* gene (K13, *P. falciparum* 3D7_1343700) ([@bib4]). This finding was further supported by genome-wide association studies, which identified a region of chromosome 13 to be associated with slow parasite clearance ([@bib9]; [@bib43]). Multiple reports from the GMS and other areas from Asia, Africa and Latin America ensued and the identification of more than 200 different non-synonymous mutations in the Kelch domain of the K13 protein (codons 441--726) ([@bib27]; [@bib36]; [@bib43]; [@bib47]; [@bib52]). Parasites engineered to have some of these mutations conclusively showed increased ring-stage survival after exposure to ART *in vitro* ([@bib15]; [@bib42]). Although the molecular mechanism of K13-mediated ART resistance is not completely understood, an upregulated unfolded response pathway was observed in clinically ART-resistant parasites with mutant K13 genes by transcriptome analysis ([@bib31]). In addition, K13 mutations were also implicated to act via phosphatidylinositol-3-kinase signaling ([@bib26]). Certain K13 mutations were found to enhance the parasite\'s stress response involving the ubiquitin/proteasome pathway, as resistant parasites harboring K13 mutations showed reduced ubiquitination ([@bib12]).

Given the different drug histories and evolutionary backgrounds ([@bib45]), there is substantial geographic heterogeneity within the GMS with regard to the patterns as well as frequencies of K13 mutations ([@bib20]; [@bib47]). C580Y was the most prevalent mutation and approached fixation in western Cambodia, whereas in the Thai--Cambodian/Thai--Myanmar border areas C580Y, Y493H, R539T, and I543T were all present ([@bib4]; [@bib36]; [@bib44]; [@bib46]). In northern Myanmar and the China--Myanmar border areas, F446I was the most prevalent and showed association with reduced ART susceptibility ([@bib20]; [@bib52], [@bib48]). The heterogeneity in K13 mutations over the whole GMS requires a regional approach to study the occurrence and spread of ART resistance in this area. At the China-Myanmar border area, where ART family drugs have been used for over three decades, there have been reports of an increase in the day-3 parasite-positive cases and increased prevalence of K13 mutations ([@bib20]; [@bib52], [@bib48]), suggesting possible emergence of ART resistance.

In this study, K13 polymorphisms were investigated in longitudinally archived parasite samples from the China-Myanmar border. *In vitro* sensitivities of the parasites to AS and dihydroartemisinin (DHA) were evaluated using the 72 h traditional SYBR Green I-based assay (EC~50~^72h^) and the ring survival assay (RSA^6h^), where early (0--3 h) ring-stage parasites were exposed to DHA for 6 h, in order to track the evolution of ART resistance in the parasite populations over a 10-year period.

2. Materials and methods {#sec2}
========================

2.1. Sample collection {#sec2.1}
----------------------

*P. falciparum* clinical isolates were collected in 2007--2016 from the China-Myanmar border. Most isolates were convenience samples collected at local health facilities. Giemsa-stained thick smears were made on febrile patients with uncomplicated malaria to identify *P. falciparum* infections. Written informed consent was signed by the patients or by the guardians of children before enrollment into this study. Prior to drug treatment, up to 5 ml of venous blood were drawn from patients, cryopreserved and stored in liquid nitrogen. Patients were then treated with DHA-piperaquine per local malaria treatment guidelines. Treatment was generally not supervised and the outcome was not followed. Monoclonal infections were determined by analysis of the *merozoite surface protein 1* (*msp1*) and *msp2*) and *glutamate-rich protein* (*glurp*) genes as described earlier ([@bib28]; [@bib57]). Only isolates with monoclonal infections were used for drug assays. The study was approved by the Institutional Review Boards of Pennsylvania State University, Kunming Medical University, China Medical University and Department of Health of Kachin.

2.2. *In vitro* culture of parasites {#sec2.2}
------------------------------------

Samples of frozen strains were thawed in solutions of NaCl and glucose. *P. falciparum* parasite isolates were cultured in RPMI 1640 culture medium with 6% human AB serum, supplemented with 0.5% Albumax II. Cultures were maintained in 90% N~2~, 5% O~2~ and 5% CO~2~. In general, about three weeks of continuous culture were performed before the parasites were used for drug assays.

2.3. Drug susceptibility assay {#sec2.3}
------------------------------

Sensitivities of the parasite isolates to AS and DHA were assessed using a standard SYBR green I-based assay with a 72 h duration and using 3D7 as the reference strain ([@bib41]; [@bib50]). Parasites in the ring stage were tightly synchronized by 5% D-sorbitol, and diluted to 2% hematocrit and 0.5% parasitemia with complete medium. Drug assay was conducted in 96-well culture plates with different concentrations of drugs. Results were expressed as the 50% effective concentration (EC~50~) calculated from the variable-slope sigmoidal function for each measurement. Each isolate was measured in three biological experiments, each with two technical replicates.

2.4. Ring survival assay {#sec2.4}
------------------------

RSA was performed as previously described ([@bib40]; [@bib54]; [@bib59]). Briefly, highly synchronous parasite cultures at the young ring stage (0--3 h) were exposed to 700 nM DHA or 0.1% dimethyl sulfoxide (DMSO) as the control for 6 h. The drugs were then washed off with RPMI 1640, and parasites cultivated further for 66 h under the standard *in vitro* culture conditions. At 72 h after the assay initiation, survival rates were calculated in Giemsa-stained thin smears by counting the viable parasites surviving in DHA-treated versus DMSO-treated cultures. Parasite isolates demonstrating \>1% survival in the RSA were considered to display reduced susceptibility to ART ([@bib2]). The RSA value of each parasite isolate was determined in three biological replicates.

2.5. Amplification and sequencing of K13 gene {#sec2.5}
---------------------------------------------

DNA was extracted from the blood samples by using the High Pure PCR Template Preparation Kit (Roche, Germany) following the manufacturer\'s instructions. The full-length *K13* gene was amplified by three nested PCR reactions and sequenced by using the Sanger sequencing method. Specific primers and cycling conditions are listed in [Table S1](#appsec1){ref-type="sec"}. Assembly and alignment of DNA sequences were performed using the DNASTAR software.

2.6. Statistical analysis {#sec2.6}
-------------------------

All data were analyzed with Microsoft Excel and GraphPad Prism 6.0. Normally distributed data were expressed as means with standard deviations, while data that were not normally distributed were expressed as medians with interquartile ranges (IQR). Mann-Whitney *U* test was used to compare between two groups. The EC~50~^72h^ value for each drug was estimated using GraphPad Prism 6.0. Estimates of EC~50~ and RSA survival rates were analyzed with one-way ANOVA. Fisher\'s exact test was used to compare mutation frequency data between two groups. For data involving multiple comparisons, *P* values were corrected using the Benjamini-Hochberg procedure ([@bib6]).

3. Results {#sec3}
==========

3.1. *In vitro* sensitivities of adapted field isolates to AS and DHA {#sec3.1}
---------------------------------------------------------------------

A total of 133 field parasite isolates collected between 2007 and 2016 from the China-Myanmar border area were selected for this study. Parasites were culture-adapted and confirmed to be monoclonal after genotyping three polymorphic genes, *msp1*, *msp2* and *glurp* ([@bib28]). *In vitro* susceptibilities to AS and DHA of 133 parasite isolates and the laboratory clone 3D7 were tested using the 72 h SYBR Green I assay and RSA ([Fig. 1](#fig1){ref-type="fig"}A and B and [Table 1](#tbl1){ref-type="table"}). The mean EC~50~^72h^ values for the 133 field parasite isolates were 11.2 nM (range 1.8--26.5 nM) to AS and 4.2 nM (range 1.7--11.0 nM) to DHA, which were ∼2 fold higher than those for 3D7 (*P* \< 0.05, Mann Whitney *U* test). EC~50~^72h^ values for both AS and DHA showed significant differences among the years (*P* \< 0.001, one-way ANOVA), but they did not follow a clear trend over the years. RSA^6h^ values of the 133 clinical isolates (4.3%) were significantly higher than that for 3D7 ([Table 1](#tbl1){ref-type="table"}). The range of the RSA^6h^ values for the field isolates was relatively wide (0--19.4%). If the 1% RSA value is used as the cutoff value for ART resistance, 117 (88.0%) parasite isolates had RSA values greater than 1%. It is noteworthy that RSA^6h^ values rose consistently from 2007 to 2016 with significant difference in samples obtained after 2013 when compared to samples collected before 2009 (*P* \< 0.05, Mann-Whitney *U* test) ([Fig. 1](#fig1){ref-type="fig"}C & [Table 1](#tbl1){ref-type="table"}). Pair-wise comparison between the RSA^6h^ and EC~50~^72h^ values for both AS and DHA showed no significant correlation (*P* \> 0.05, Spearman\'s correlation test) ([Fig. S1](#appsec1){ref-type="sec"}).Fig. 1***In vitro* susceptibilities of 133 *P. falciparum* parasite isolates from the China-Myanmar border to two artemisinin derivatives stratified by years. (A)** EC~50~^72h^ values (nM) to artesunate; **(B)** EC~50~^72h^ values (nM) to dihydroartemisinin; **(C)** Ring-stage survival rates after exposure of ring-stage parasites to 700 nM of dihydroartemisinin for 6 h \*, \*\*, \*\*\*, and \*\*\*\* denote significance at *P* \< 0.05, 0.01, 0.001, and 0.0001, respectively (Mann-Whitney *U* test).Fig. 1Table 1Susceptibilities of *P. falciparum* parasites collected in different years to artesunate and dihydroartemisinin.Table 1YearNAS EC~50~ (nM)\**P*DHA EC~50~ (nM)\**P*RSA (%)^\#^*P*20071712.4 ± 3.3\<0.0001[a](#tbl1fna){ref-type="table-fn"}4.5 ± 2.30.0002[a](#tbl1fna){ref-type="table-fn"}2.1 (0.9--7.5)0.1353[a](#tbl1fna){ref-type="table-fn"}2008199.7 ± 2.84.3 ± 2.02.4 (1.2--4.7)20091411.8 ± 4.15.1 ± 1.75.3 (1.2--9.8)2010--2012914.9 ± 5.15.0 ± 1.94.9 (0.6--10.6)2013407.8 ± 3.33.2 ± 1.15.0 (3.0--8.1)2014--20163414.2 ± 6.44.6 ± 1.84.8 (3.2--6.3)Total13311.2 ± 5.1\<0.0001[b](#tbl1fnb){ref-type="table-fn"}4.2 ± 1.8\<0.0001[b](#tbl1fnb){ref-type="table-fn"}4.3 (1.9--7.5)\<0.0001[b](#tbl1fnb){ref-type="table-fn"}3D75.0 ± 0.12.4 ± 0.20[^2][^3][^4]

3.2. K13 gene polymorphisms {#sec3.2}
---------------------------

Full-length K13 genes were amplified from the 133 culture-adapted field isolates and sequenced. A total of 11 single nucleotide polymorphisms (SNPs) were detected, all being nonsynonymous mutations. Of the 11 amino acid (aa) mutations, two (K189T and E252Q) are located before the Kelch propeller domain (\<440 aa), while nine (P441L, F446I, N458Y, G533S, R539T, P574L, C580Y, A676D, and H719N) are within the propeller domain (\>440 aa). In addition, an NN insertion at 136--137 aa (this is outside of the propeller and the BTZ domains) was observed in 103 (77.4%) parasite isolates ([Table 2](#tbl2){ref-type="table"}). Compared with the 3D7 K13 sequence, 20 (15%) were wild-type (WT) K13 gene, whereas 113 (85%) carried the NN insertion and/or SNPs. Of the 85 (63.9%) parasites that carried nonsynonymous SNPs, only one parasite from 2008 carried two nonsynonymous SNPs (E252Q and F446I) in the same gene. Interestingly, the NN insertion gradually increased its frequency and approached fixation after 2014. Among the SNPs, seven were observed in earlier samples collected in 2007--2009. F446I was the most predominant mutation, and its frequency increased from 17.6% (3/17) in 2007 to 55.9% (19/34) in 2014--2016. A new mutation, G533S, never reported earlier in China-Myanmar border, appeared in the latest samples obtained in 2014--2016 and was the second most prevalent mutation (44.1%) in these samples ([Table 2](#tbl2){ref-type="table"}). The rest of the mutations were relatively rare (\<2.3%). Specifically, the C580Y and R539T mutations associated with delayed parasite clearance and common in other areas of GMS were only found in one sample each. For mutations outside the Kelch domain, two samples from 2008 carried the E252Q mutation, while two samples from 2013 carried the K189T mutation.Table 2Prevalence (%) of mutations in the *K13* gene in clinical isolates from the China-Myanmar border.Table 2YearnNN[a](#tbl2fna){ref-type="table-fn"}K189TE252QP441LF446IN458YG533SR539TP574LC580YA676DH719N20071747.1----5.917.6------11.8------20081947.4--10.5--21.1----5.35.35.35.3--20091464.3------7.1----------7.121.42010--2012977.8------33.3--------------20134090.05.0----62.52.5------------2014--201634100.0------55.9--44.1----------Total13377.41.51.50.841.40.811.30.82.30.81.52.3[^5]

3.3. Correlation of K13 mutations with RSA phenotypes {#sec3.3}
-----------------------------------------------------

We next performed statistical analysis to determine whether certain K13 genotypes were associated with altered drug susceptibilities. Since the mutations in the propeller domain of K13 protein (\>440 aa) were associated with clinical ART resistance, we grouped the 133 parasites into two groups based on the presence or absence of mutations in the propeller domain. Parasites with mutations in the propeller domain showed a median RSA^6h^ value of 5.1%, significantly higher than 2.9% in the K13 WT group (*P* = 0.0021, Mann Whitney *U* test) ([Fig. 2](#fig2){ref-type="fig"}A). One parasite isolate with R539T and two isolates with A676D showed RSA values of \>15%. The two most common mutations, F446I (55 isolates) and G533S (15 isolates), also showed significantly higher median RSA^6h^ values of 5.2% (*P* = 0.002) and 4.6% (*P* = 0.0193), respectively, than the WT. Some parasites with the K189T (2 isolates) and E252Q (2 isolates) mutations before the propeller domain also displayed RSA^6h^ values \> 1% and median values higher than that of the WT parasites, whereas a single parasite isolate carrying the C580Y mutation had a comparable RSA value to that of the 3D7 parasite ([Fig. 2](#fig2){ref-type="fig"}B, [Table 3](#tbl3){ref-type="table"}). The parasites with the K13 NN insertion showed a slightly higher mean RSA value (4.4%) than that of the parasites without the NN insertion (4.2%), although the difference was not significant (*P* \> 0.05, Mann Whitney *U* test). Interestingly, parasites carrying the mutations in the K13 propeller domain also showed significantly higher EC~50~^72h^ values to AS than WT parasites ([Fig. S2](#appsec1){ref-type="sec"}), although the EC~50~^72h^ values to DHA were not significantly different between the two groups. In addition, WT parasites and parasites with the NN insertion had similar EC~50~^72h^ values to either AS or DHA.Fig. 2**Correlation of parasite survival rates (RSA**~**0-3h**~**) and *K13* polymorphisms**. (A) RSA values between parasites with mutations in the kelch propeller domain (\>440 mutations) and parasites without kelch mutations (\>440 WT). Different K13 mutations were color-coded. *P* = 0.0021 (Mann-Whitney *U* test). **(B)** Comparison of RSA values between parasites with different K13 mutations and the wild type (WT). *P* values were from Mann-Whitney *U* test with Benjamini-Hochberg correction. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 2Table 3Ring **s**urvival rates (RSA~0--3h~) of parasite isolates stratified by the *K13* alleles.Table 3MutationsnMedian RSA (%)IQR*P\**WT^\#^482.51.0--4.9--K189T28.97.5--10.40.1403[a](#tbl3fna){ref-type="table-fn"}E252Q25.23.0--7.40.451[a](#tbl3fna){ref-type="table-fn"}P441L10.5--0.0003[b](#tbl3fnb){ref-type="table-fn"}F446I555.23.1--8.20.002[a](#tbl3fna){ref-type="table-fn"}N458Y17.5--0.0003[b](#tbl3fnb){ref-type="table-fn"}G533S154.63.3--7.10.0193[a](#tbl3fna){ref-type="table-fn"}R539T115.3--0.0003[b](#tbl3fnb){ref-type="table-fn"}P574L31.61.3--11.70.921[a](#tbl3fna){ref-type="table-fn"}C580Y10.0--0.0003[b](#tbl3fnb){ref-type="table-fn"}A676D216.715.6--17.70.0061[a](#tbl3fna){ref-type="table-fn"}H719N35.41.3--8.80.4571[a](#tbl3fna){ref-type="table-fn"}[^6][^7][^8][^9]

4. Discussion {#sec4}
=============

Through analysis of 133 longitudinally collected clinical samples spanning a decade from the China-Myanmar border area, we detected reduced *in vitro* sensitivities against two ART drugs, as well as elevated RSA^6h^ values indicative of clinical ART resistance. This was further supported by escalating prevalence of K13 mutant alleles that are correlated with increased ring survival rates. There has been a substantial decline of malaria burden in the GMS, where multidrug-resistant parasites have been rampant. Different drug policies in neighboring countries in the GMS affect the course of evolution of drug resistance ([@bib58]), and therefore constant surveillance of drug efficacy and resistance is required to ensure timely adjustment of frontline drugs. Notably, international borders in the GMS are extremely porous with high malaria transmission intensity ([@bib10]; [@bib37]), which make the two sides of the border very prone to influx of drug-resistant parasites. Hence, in light of the recently emerged ART resistance in *P. falciparum* in the GMS, the current study aimed to follow the trend of ART-resistant parasites in the China-Myanmar border area. Together with previous reports documenting delayed parasite clearance, the presence of day-3 positive parasites after ART/ACT treatments, and the high prevalence of K13 polymorphisms in the same border area ([@bib22]; [@bib36]; [@bib52]), this study revealed an increasing trend of reduced ART susceptibility in the *P. falciparum* population at the China-Myanmar border.

Taking advantage of longitudinally archived parasites collected between 2007 and 2016, we evaluated their sensitivities to ART drugs using both EC~50~^72h^ estimates quantifying parasite proliferation and RSA^6h^ estimating parasite survival at early ring stage. Our data showed significant differences in drug sensitivity over the ten-year period. Parasites banked in different years showed fluctuation of the EC~50~^72h^ values to both AS and DHA without a clear trend, but the RSA^6h^ data distinctly showed an evident gradual increase over the period of ten years. Consistent with our earlier finding ([@bib52]), we did not detect significant correlation between the values of the two drug assays, although they both may be intrinsically linked to clinical resistance. It is noteworthy that in the earlier years of emergence of ART resistance in the GMS, a west-to-east increasing trend of EC~50~^72h^ values estimated using ex vivo 72 h drug assay was reported ([@bib34]). Given that RSA^6h^ is considered to be able to capture the delayed parasite clearance phenotype attributed to prolonged and dormant ring stages ([@bib19]; [@bib52]; [@bib55]), the escalating RSA^6h^ values in parasites collected after 2008 suggest a possible emergence of ART resistance in these latter parasites, which are concomitant with the widespread use of ACT in the study area.

A number of mutations in the Kelch propeller domain of K13 were associated with delayed clearance in clinical studies ([@bib5]). Genotyping analysis for our 133 parasite samples in this study revealed 11 distinct nonsynonymous mutations, of which 9 occurred in the propeller domain. All these mutations have been described previously in Myanmar or the China-Myanmar border area except G533S ([@bib4]; [@bib5]; [@bib14]; [@bib36]; [@bib47]; [@bib51]). The parasite population at the China-Myanmar border bears more resemblance to parasite population collected from northern Myanmar, where F446I was the predominant mutation ([@bib4]; [@bib36]; [@bib47]; [@bib51]). However, it is drastically different from parasite populations from most parts of the GMS. Mutations prevalent in other GMS countries or regions were either completely absent (e.g., I543T and Y493H) or occurred at very low frequencies (C580Y and R539T) in our study population ([@bib4]; [@bib5]; [@bib56]). Mutations associated with high RSA^6h^ values but present sparsely in these samples include R539T, A676D and N458Y. A676D has been reported earlier in various studies from the China-Myanmar area but it does not seem to confer ART resistance ([@bib1]; [@bib14]; [@bib52]; [@bib53]; [@bib56]), whereas N458Y showed significant association with prolonged parasite clearance half-lives in clinical studies ([@bib4]; [@bib5]; [@bib47]), and also showed very high ring-stage survival rate (60%) in our previous study ([@bib52]). While the reasons underlying these geographical differences in K13 mutations are not clear, differences in drug histories and genetic backgrounds of these parasites are likely among the answers ([@bib29]). Our temporal data revealed that the genetic diversity of K13 was much higher in earlier years (2007--2009), whereas in samples after 2010, the K13 mutations were predominated by F446I and G533S, with the latter only showing up in the 2014--2016 samples and also attaining high prevalence (44.1%). This implies that these two mutations might confer fitness advantages to the parasites under the current ACT regimen in this region.

The most prevalent mutation in our sample set, F446I, is associated with significantly higher ring survival rates (RSA^6h^) than the WT parasites. Interestingly, its prevalence showed a continuous increase from 2007 to 2016. This mutation has been the most common in the northern part of GMS including Myanmar and the China-Myanmar border area ([@bib14]; [@bib20]; [@bib47]; [@bib51], [@bib52]), but it is lacking in other areas of SE Asia ([@bib56]). Clinical studies showed that F446I was significantly associated with delayed parasite clearance and day-3 positive parasites in the China--Myanmar border region ([@bib20]; [@bib52]). Recently the role of F446I in mediating ART resistance was confirmed genetically by introduction of this mutation into ART-sensitive laboratory strains ([@bib48]).

The K13 propeller domain consists of six blades: P441L, F446I, and N458Y are located in Blade I, G533S and R539T in Blade III, P574L and C580Y in Blade IV, and A676D and H719N in Blade VI ([@bib4]). One of the newly found mutations with high prevalence in this geographical location is G533S. This mutation has been reported earlier in *P. falciparum* samples from Cambodia and Gambia ([@bib1]; [@bib4]), whereas an alternative form of this mutation G533A has also been reported from India ([@bib30]). In our field samples, this mutation appeared for the first time in the most recent samples, and parasites with this mutation showed significantly higher ring survival rates than the WT parasites. Glycine (G), being the smallest amino acid, has the highest conformational flexibility and its substitution by either the polar uncharged serine (S) or the hydrophobic alanine (A) may lead to some structural and functional alterations. Although both substitutions are predicted to be neutral/tolerated for K13 using Provean and SIFT analysis ([@bib25]; [@bib40]), G533S may influence the disulfide bond between C532 and C580 in the protein. G to S mutations have also been reported to affect protein stability, resulting in adverse phenotypes in other systems ([@bib35]; [@bib60]), whereas G to A mutation is generally considered to be well tolerated ([@bib24]). It would be interesting to test the prediction of the structural effects of these mutations on ART resistance by genetic manipulation.

Whereas mutations present in the kelch domain are associated with ART resistance, this study also revealed two point mutations, E252Q and K189T in 2008 and 2013, respectively, outside the Kelch domain. Although these parasites show relatively high RSA values but due to their low frequencies in the sample set and absence of any gene manipulation data, no association can be concluded. Interestingly, E252Q was also the most common mutation before 2011 on the Thai-Myanmar border, and has been recently associated with slow parasite clearance and elevated treatment failure rates ([@bib3]; [@bib38]). This mutation was found only in two field isolates from 2008. It is argued that these parasites might be progressively taken over by the ones with *K13* propeller mutations, leading to even slower clearance rates ([@bib3]). The potential role of the E252Q in mediating ART resistance remains to be determined genetically. Another interesting finding from this analysis was the increasing prevalence of parasites with NN insertion at position 136--137, which reached 100% in the most recent parasite samples. Our earlier analysis of a small sample set showed that this insertion was present only in day-3 parasite-positive isolates showing association with increased ring stage survival ([@bib52]). However, we did not detect a significant association of the NN insertion with altered sensitivity to ART drugs, suggesting that our earlier observation could be due to concurrent Kelch mutations in the NN insertion samples. Since parasites with minisatellite variations in the *nhe1* gene show altered sensitivities to quinine ([@bib28]), it would be interesting to test the NN insertion in K13 gene with regard to ART sensitivity.

Besides confirming the contribution of Kelch mutations to increased ring survival rates, we also found a wide range of RSA^6h^ values (0--19.4%) for parasites without the Kelch mutations. Field isolates lacking K13 mutations but showing ART-resistant phenotype were also identified previously in Cambodia ([@bib32]). This indicates involvement of secondary and/or additional mechanisms in ART resistance. We recently reported that falcipain 2a (FP2a) may be an additional contributor to ART resistance as FP2a mutations are associated with reduced enzyme activity, decreased hemoglobin digestion and elevated ring-stage survival after DHA treatment ([@bib21]; [@bib40]). Genome-wide association studies and gene manipulation experiments have also identified other genetic loci (e.g., ATG18, coronin, pfap2mu) possibly associated with ART resistance ([@bib7]; [@bib11]; [@bib17]; [@bib29]; [@bib50]).

This study has a few limitations. Although efficacy studies in recent years showed excellent clinical efficacies of ACT for treating uncomplicated falciparum malaria in this region ([@bib23]; [@bib49]), the majority of the clinical samples in this study was convenience samples without a link to the clinical outcomes of the treatment. In addition, although we strived to increase the accuracy of the RSA by performing three biological replicates of the assay, the use of flow cytometry deploying a mitochondrial marker along with SYBR Green staining will further enhance the precision of the results compared to microscopic examination as the read-out for RSA ([@bib16]). Furthermore, it is noteworthy that there is substantial variability in the RSA results among different laboratories, and the establishment of standardized control isolates will allow better comparison of results from different studies. The small sample numbers collected in certain years make it difficult to draw firm conclusions for association of certain K13 genotypes with reduced ART susceptibility.

Emergence and spread of ART-resistant parasites are a major concern for malaria control and elimination, which justifies continuous monitoring of K13 polymorphisms. In this regard, *in vivo* observation of clinical efficacy, *in vitro* (or ex vivo) RSA and K13 genotyping all serve as complementary predictive markers in epidemiological surveillance of ART resistance ([@bib4]; [@bib5]; [@bib52]). Our data further confirm the emergence and/or spread of *P. falciparum* parasites with reduced ART sensitivity at the China-Myanmar border. Parasites showing increased ring survival rates but lacking the K13 mutations indicate additional mechanisms of ART resistance. Taken together, these findings imply an urgent need for increased regional and phenotypic surveillance and population studies to determine new ART resistance mechanism and monitor the spread of ART resistance in the GMS for designing better containment strategies.
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